About BillionToOne
BillionToOne is a company based in San Francisco (United States) founded in 2015 by Oguzhan Atay. BillionToOne has raised $388.62 million across 10 funding rounds from investors including HHS, Baillie Gifford and Bridge Community Bank. The company has 47 employees as of December 31, 2020. BillionToOne offers products and services including UNITY Screen™, Northstar Select™, and Northstar Response™. BillionToOne operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter San Francisco, United States
- Employees 47 as on 31 Dec, 2020
- Founders Oguzhan Atay
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Billiontoone, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$388.62 M (USD)
in 10 rounds
-
Latest Funding Round
$130 M (USD), Series D
Jun 21, 2024
-
Investors
HHS
& 19 more
-
Employee Count
47
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BillionToOne
BillionToOne is a publicly listed company on the NASDAQ with ticker symbol BLLN in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BillionToOne
BillionToOne offers a comprehensive portfolio of products and services, including UNITY Screen™, Northstar Select™, and Northstar Response™.
Assesses fetal risk for recessive conditions and aneuploidies using maternal blood.
Determines appropriate first-line therapy for cancer patients.
Monitors effectiveness of cancer therapies through testing.
People of BillionToOne
Unlock access to complete
Unlock access to complete
Funding Insights of BillionToOne
BillionToOne has successfully raised a total of $388.62M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $130 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BillionToOne
BillionToOne has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Baillie Gifford and Bridge Community Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides venture capital for technology startups and enterprise innovations worldwide.
|
Locked | Locked | Locked | |
|
Secondary market fund focused on LP and direct secondary transactions
|
Locked | Locked | Locked | |
|
Private markets investment management with strategies in equity, credit, and secondary investments.
|
Locked | Locked | Locked |
Investor details for BillionToOne
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BillionToOne
Investment portfolio details for BillionToOne
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BillionToOne
Detailed financials for BillionToOne
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Billiontoone Comparisons
Peer comparison for BillionToOne
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BillionToOne
BillionToOne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Detailed competitors of BillionToOne
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Billiontoone
Complete news archive for BillionToOne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BillionToOne
BillionToOne was founded in 2015 and raised its 1st funding round 2 years after it was founded.
BillionToOne is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Oguzhan Atay is the current CEO of BillionToOne. They have also founded this company.
BillionToOne is a funded company, having raised a total of $388.62M across 10 funding rounds to date.
As of Dec 31, 2020, the latest employee count at BillionToOne is 47.
BillionToOne was founded in 2015 in San Francisco, United States, within the biotechnology sector. Cell-free cancer liquid biopsy tests are offered, supported by a molecular counter platform that analyzes DNA molecules from blood samples. Additional genetic tests are provided for conditions including cystic fibrosis, spinal muscular atrophy, and sickle cell disease. Operations center on diagnostic services for oncology and inherited disorders.
BillionToOne's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
BillionToOne offers UNITY Screen™, Northstar Select™, and Northstar Response™.
Yes, BillionToOne is publicly traded on NASDAQ under the ticker symbol BLLN.
BillionToOne has 20 investors. Key investors include HHS, Baillie Gifford, Bridge Community Bank, Neuberger Berman, and Norwest Venture Partners.
The ticker symbol of BillionToOne is BLLN on NASDAQ.